Phaedra Chrousos - Jun 14, 2021 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role: Director
Signature: /s/ Phaedra Chrousos
Stock symbol: VNDA
Transactions as of: Jun 14, 2021
Transactions value $: -$40,132
Form type: 4
Date filed: 6/15/2021, 04:42 PM
Previous filing: Jun 14, 2021
Next filing: Jun 21, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VNDA	Common Stock	Sale	-$40.1K	-2.08K	-13.83%	$19.34	12.9K	Jun 14, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.33 to $19.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Content

Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.33 to $19.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.